Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

da VINci Study (OTSGC-A24 Therapeutic Peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study

Next Previous
Search
Trial Profile

da VINci Study (OTSGC-A24 Therapeutic Peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gastric cancer vaccine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms da VINci

    • Most Recent Events

    • 07 Mar 2024 Last checked against ClinicalTrials.gov record.
    • 13 Sep 2022 Results (n=25; from February 2019 to November 2021) assessing the safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer, presented at the 47th European Society for Medical Oncology Congress.
    • 05 Apr 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top